H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 27.3 HKD -2.15% Market Closed
Market Cap: 23.8B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

HUTCHMED (China) Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HUTCHMED (China) Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
H
HUTCHMED (China) Ltd
HKEX:13
Accounts Payable
$43.4m
CAGR 3-Years
15%
CAGR 5-Years
11%
CAGR 10-Years
4%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Accounts Payable
HK$3.5B
CAGR 3-Years
63%
CAGR 5-Years
38%
CAGR 10-Years
20%
S
SSY Group Ltd
HKEX:2005
Accounts Payable
HK$450.4m
CAGR 3-Years
12%
CAGR 5-Years
21%
CAGR 10-Years
1%
U
United Laboratories International Holdings Ltd
HKEX:3933
Accounts Payable
ÂĄ5.3B
CAGR 3-Years
27%
CAGR 5-Years
16%
CAGR 10-Years
6%
Sino Biopharmaceutical Ltd
HKEX:1177
Accounts Payable
ÂĄ2.2B
CAGR 3-Years
10%
CAGR 5-Years
-2%
CAGR 10-Years
18%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Accounts Payable
HK$141.9B
CAGR 3-Years
41%
CAGR 5-Years
27%
CAGR 10-Years
N/A
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
23.8B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. The company employs 1,759 full-time employees The company went IPO on 2006-05-19. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Intrinsic Value
21.49 HKD
Overvaluation 21%
Intrinsic Value
Price
H

See Also

What is HUTCHMED (China) Ltd's Accounts Payable?
Accounts Payable
43.4m USD

Based on the financial report for Jun 30, 2024, HUTCHMED (China) Ltd's Accounts Payable amounts to 43.4m USD.

What is HUTCHMED (China) Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
4%

Over the last year, the Accounts Payable growth was -20%. The average annual Accounts Payable growth rates for HUTCHMED (China) Ltd have been 15% over the past three years , 11% over the past five years , and 4% over the past ten years .

Back to Top